Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2023.

Details are as follows:

Citi’s 18th Annual BioPharma Conference Location: Boston, MAFormat: 1x1 MeetingsDate: Thursday, September 7

H.C. Wainwright 25th Annual Global Investment Conference Location: New York, NY Format: Presentation Date: Monday, September 11Time: 4:00 PM ET Webcast Link: https://journey.ct.events

Cantor Fitzgerald Global Healthcare Conference Location: New York, NY Format: Fireside Chat Date: Wednesday, September 27Time: 2:25-2:55 PM ET Webcast Link: https://wsw.com/webcast/cantor19/cmpx

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact[email protected]

Media ContactAnna Gifford, Communications Manager[email protected] 617-500-8099

You May Also Be Interested In

• Trupanion to Participate in Virtual Fireside Chat with Piper Sandler
• CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes
• Fuel Tech Set to Join Russell Microcap® Index